Zobrazeno 1 - 10
of 73
pro vyhledávání: '"S. Henschen"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Sven Schiermeier, UH Bircok, B Gualeni, C Zumdick, H Asrar, A Töpfer, F Badbanchi, A Balog, S Becht, A Opazo-Saez, N Filmann, C Mau, S Schoen, J Reinhard, T Cordes, S Henschen, H Busse, M Eichbaum
Publikováno v:
Geburtshilfe und Frauenheilkunde.
Autor:
Michele Moschetta, Abigail Evans, S. Henschen, Rachel Wuerstlein, Kwok-Leung Cheung, Teresa Klinowska, Ashutosh Kothari, A Jahan, Cliona C. Kirwan, Justin P.O. Lindemann, Myria Nikolaou, Diansong Zhou, Martine P. Roudier, John F.R. Robertson, Omar Mohamed, J Michael Dixon, Alexander MacDonald, Danielle Carroll, Nadia Harbeck, Peter Schmid, Rhiannon Maudsley, Richard Mather, Li Zhou, Peter A. Fasching, Tinnu Sarvotham, Gaia Schiavon, Laura M. Kenny
Publikováno v:
Robertson, J F R, Evans, A, Henschen, S, Kirwan, C C, Jahan, A, Kenny, L M, Dixon, J M, Schmid, P, Kothari, A, Mohamed, O, Fasching, P A, Cheung, K-L, Wuerstlein, R, Carroll, D, Klinowska, T, Lindemann, J P O, MacDonald, A, Mather, R, Maudsley, R, Moschetta, M, Nikolaou, M, Roudier, M P, Sarvotham, T, Schiavon, G, Zhou, D, Zhou, L & Harbeck, N 2020, ' A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2-Primary Breast Cancer ', Clinical cancer research : an official journal of the American Association for Cancer Research . https://doi.org/10.1158/1078-0432.CCR-19-3387
Purpose:Fulvestrant, the first-in-class selective estrogen receptor (ER) degrader (SERD), is clinically effective in patients with ER+ breast cancer, but it has administration and pharmacokinetic limitations. Pharmacodynamic data suggest complete ER
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::022f3127e21e4eed7b6bf141c835259d
https://research.manchester.ac.uk/en/publications/5e7ad486-ebaa-4ad6-aaec-b5514165fac0
https://research.manchester.ac.uk/en/publications/5e7ad486-ebaa-4ad6-aaec-b5514165fac0
Autor:
Tanja Fehm, Carolin C. Hack, R. Landthaler, J.-U. Deuker, Rachel Wuerstlein, Daniela Rezek, C Brucker, G. Fischer, Peter Dall, Peter A. Fasching, H.-W. Vollert, T. Praetz, M. Popovic, Mahdi Rezai, T Noesselt, Sara Y. Brucker, M. Guggenberger, V. Heyl, J. de Waal, G. Wachsmann, Barbara Richter, P. Hadji, S. Henschen, J.W. Siebers, M Warm, Thorsten Kühn, C. Thomssen, Hans-Christian Kolberg, A. Hohn, Thomas Krauss, C. Wolf, M. W. Beckmann, Lothar Häberle, Erik Belleville, Alexander Hein, Katja Schmidt, Diethelm Wallwiener, G. Baake, A. Kohls, Sherko Kümmel, B. Baier, Christoph Mundhenke, Wolfgang Janni, Hans Tesch, Naiba Nabieva, G. P. Breitbach, Nadia Harbeck
Publikováno v:
European Journal of Cancer. 96:82-90
Background Endocrine treatment (ET) with an aromatase inhibitor (AI) is the treatment of choice in post-menopausal patients with hormone receptor–positive early breast cancer (EBC). However, adverse events (AEs) often lead to treatment discontinuat
Autor:
Sara Y. Brucker, C Brucker, Katja Schmidt, J. de Waal, V. Heyl, T. Praetz, P. Hadji, G. Wachsmann, Daniela Rezek, Peter A. Fasching, A. Jacob, J.-U. Deuker, Christian M. Bayer, Peter Dall, M Warm, G. Baake, Thomas Krauss, T Noesselt, Rachel Wuerstlein, Wolfgang Janni, Hans Tesch, Naiba Nabieva, G. Fischer, C. Wolf, M. Guggenberger, A. Hohn, M. W. Beckmann, G. P. Breitbach, Nadia Harbeck, Hans-Christian Kolberg, Barbara Richter, H.-W. Vollert, A. Kohls, Erik Belleville, Alexander Hein, Sherko Kümmel, R. Landthaler, Diethelm Wallwiener, Lothar Häberle, Nikos Fersis, Mahdi Rezai, B. Baier, C. Thomssen, Claudia Rauh, Christoph Mundhenke, S. Henschen, Thorsten Kühn, J.W. Siebers, S. Kellner, Tanja Fehm
Publikováno v:
Annals of Oncology. 29:186-192
Background Patients’ compliance and persistence with endocrine treatment has a significant effect on the prognosis in early breast cancer (EBC). The purpose of this analysis was to identify possible reasons for non-persistence, defined as premature
Autor:
Christian Löhberg, C Brucker, Rachel Wuerstlein, P Gaß, S. Henschen, V. Heyl, Diethelm Wallwiener, Thorsten Kühn, J.W. Siebers, Hans-Christian Kolberg, Daniela Rezek, T. Praetz, A. Hohn, A. Jacob, Nikos Fersis, Johann de Waal, G. Baake, T Noesselt, Christoph Thomssen, Thomas Krauss, M. Guggenberger, Tanja Fehm, B. Baier, Peter A. Fasching, Barbara Richter, G. Fischer, H.-W. Vollert, Christoph Mundhenke, Katja Schmidt, Mahdi Rezai, Matthias W. Beckmann, Thomas Kuhn, Christian M. Bayer, C. Wolf, A. Kohls, Claudia Rauh, Wolfgang Janni, Hans Tesch, G. P. Breitbach, Nadia Harbeck, Peter Dall, Joerg-Uwe Deuker, R. Landthaler, Sherko Kümmel, Mathias Warm, Erik Belleville, Alexander Hein, G. Wachsmann, Sara Y. Brucker, P. Hadji
Publikováno v:
Breast Care. 11:315-322
Background: Decision-making for or against neoadjuvant or adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive breast cancer does not follow any clear guidelines, and some patients may unnecessarily undergo chemotherapy and
Autor:
Omar Mohamed, Li Zhou, Myria Nikolaou, Rhiannon Maudsley, A Jahan, Rachel Wuerstlein, Tinnu Sarvotham, Kwok-Leung Cheung, Martine P. Roudier, S. Henschen, Michele Moschetta, Teresa Klinowska, Nadia Harbeck, Peter A. Fasching, Richard Mather, Danielle Carroll, J Michael Dixon, Alexander MacDonald, Cliona C. Kirwan, Ashutosh Kothari, Justin P.O. Lindemann, Diansong Zhou, Laura M. Kenny, Gaia Schiavon, John F.R. Robertson, Peter Schmid, Abigail Evans
Publikováno v:
Cancer Research. 80:P6-04
Background: Estrogen receptor positive (ER+) breast cancer is routinely treated with endocrine therapies targeting the ER axis. However, primary and secondary resistance ultimately limits the use of these agents. Fulvestrant (FULV) is the first-in-cl
Autor:
P. Fasching, T. Fehm, S. Kellner, J. deWaal, M. Rezai, B. Baier, G. Baake, H. Kolberg, M. Guggenberger, M. Warm, N. Harbeck, R. Würstlein, J. Deuker, P. Dall, B. Richter, G. Wachsmann, C. Brucker, J. Siebers, N. Fersis, T. Kuhn, C. Wolf, H. Vollert, G. Breitbach, W. Janni, R. Landthaler, A. Kohls, D. Rezek, T. Noesslet, G. Fischer, S. Henschen, T. Praetz, V. Heyl, T. Kühn, T. Krauß, C. Thomssen, S. Kümmel, A. Hohn, H. Tesch, C. Mundhenke, A. Hein, C. Rauh, C. Bayer, A. Jacob, K. Schmidt, E. Belleville, P. Hadji, D. Wallwiener, E. Grischke, M. Beckmann, S. Brucker
Publikováno v:
Senologie - Zeitschrift für Mammadiagnostik und -therapie. 12:17-23
Einleitung: Die EvaluateTM-Studie (Evaluation of therapy management and patient compliance in postmenopausal hormone receptor positive breast cancer patients receiving letrozole treatment) ist eine prospektive, nicht interventionelle Studie, die das
Autor:
CC Hack, PA Fasching, T Fehm, J de Waal, M Rezai, B Baier, G Baake, HC Kolberg, M Guggenberger, M Warm, N Harbeck, R Wuerstlein, JU Deuker, P Dall, B Richter, G Wachsmann, C Brucker, JW Siebers, N Fersis, T Kuhn, C Wolf, HW Vollert, GP Breitbach, W Janni, R Landthaler, A Kohls, D Rezek, T Noesselt, G Fischer, S Henschen, T Praetz, V Heyl, T Kühn, T Krauß, C Thomssen, A Hohn, H Tesch, C Mundhenke, A Hein, C Rauh, CM Bayer, A Jacob, K Schmidt, E Belleville, P Hadji, SY Brucker, D Wallwiener, D Paepke, S Kümmel, MW Beckmann
Publikováno v:
Geburtshilfe und Frauenheilkunde. 76
Background: Breast cancer patients make frequent use of complementary and alternative medicine (CAM), but few prospectively collected data are available specifically for postmenopausal breast cancer patients receiving adjuvant antihormonal therapy. T
Autor:
A Pollmanns, I. Zuna, Nadia Harbeck, Bahriye Aktas, U. Nitz, H Krepe, S. Henschen, S Shak, O Gluz, Petra Krabisch, C Thomsseen, B Liedtke
Publikováno v:
Cancer Research. 71:P5-18
Background: Anthracycline-taxane based adjuvant chemotherapy (cht) is considered standard in node-positive and high-risk node-negative BC. However, retrospective analyses suggest that in HER2−BC, benefit from anthracyclines may not outweigh acute a